Rahmer Peter's Form 4 filing
Relay Therapeutics, Inc. (RLAY) · filed Sep 29, 2023
- Accession no.
- 0001209191-23-050866
- Filed
- Sep 29, 2023
- Trade date
- Jun 30-Sep 27, 2023
- Filing delay
- 91 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.04K. It was filed 91 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rahmer PeterCIK 0001959229 | Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2023 | Common Stock | AGrant or awardAcquired | +1,662 | $10.68F2 | +$17,750.16 | 319,822 | Direct | |
| Sep 27, 2023 | Common Stock | SSaleDisposed | −244 | $8.38 | −$2,044.72 | 318,226 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023.
Referenced by the price of 1 transaction in Table I.
Remarks
Title: Chief Corporate Development Officer